Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-04-02 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
2017年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2017 Annual Report Summary" of 厦门艾德生物医药科技股份有限公司 (Xiamen ADx Biopharmaceutical Technology Co., Ltd.). It contains detailed financial data for the year 2017, including revenue, net profit, quarterly financial data, shareholder information, business overview, industry analysis, and product descriptions. The document references the full annual report and includes comprehensive financial and operational information typical of an annual report. The length of the document (15,000 characters) and the detailed financial and business content confirm it is the actual report, not just an announcement or summary notice. Therefore, the document fits the definition of an Annual Report (10-K). FY 2017
2018-04-02 Chinese
关于2017年年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement from a company stating that its 2017 annual report and summary have been disclosed on the official stock exchange information website. It explicitly directs investors to review the report elsewhere and does not contain the report itself or any financial data. The document length is only 332 characters, indicating it is a brief notice rather than a full report. According to the 'Menu vs Meal' rule, such a document is classified as a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2018-04-02 Chinese
2017年年度报告
Annual Report Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司2017 年年度报告全文" which translates to "Amoy Diagnostics Co., Ltd. 2017 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the full year 2017, business overview, risk factors, industry analysis, and detailed financial metrics. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management discussion, and analysis, which are characteristic of an official annual report. There is no indication that this is merely an announcement or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2018-04-02 Chinese
2017年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year ended December 31, 2017, issued by the board of directors of Xiamen Aide Biomedical Technology Co., Ltd. It discusses the company's internal control system, evaluation procedures, control activities, risk assessment, and the effectiveness of internal controls. The document is comprehensive, contains detailed descriptions of internal control policies, risk management, and evaluation results, and is dated April 3, 2018. It is not a general annual report or earnings release but a specialized report focused on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles and internal control evaluations. The document is over 10,000 characters, indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2017
2018-04-02 Chinese
独立董事关于相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on various matters related to the company's 2017 annual report and related issues. It references the 2017 annual report, internal control self-evaluation, audit firm reappointment, accounting policy changes, and other governance and financial oversight topics. The document is a formal opinion letter from independent directors rather than the annual report itself. It does not contain full financial statements or comprehensive financial performance data but rather opinions and confirmations related to the annual report and company governance. Given the nature of the document as an independent directors' opinion on the annual report and related matters, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related regulatory or internal assessments excluding the full annual report. FY 2017
2018-04-02 Chinese
公司章程（2018年4月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 厦门艾德生物医药科技股份有限公司, dated April 2018. It contains detailed provisions on company organization, shareholder rights, board structure, share issuance, capital, and governance rules. It is a foundational governance document that sets out the internal rules and structure of the company rather than a financial report, announcement, or meeting material. There is no indication that this is an annual report, audit report, earnings release, or any other financial or regulatory filing. The content aligns with the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2018-04-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.